Zomedica Corp. · OTC:ZOMDF
Zomedica — H.C. Wainwright BioConnect Conference 2022
24 slides from Zomedica's conference presentation, January 2022
Slide 1: Zomedica
Zomedica “Making Tomorrow’s Gold Standard Available Today” Larry Heaton January 2022 Chief Executive Officer NYSE American: ZOM
Slide 2: Forward Looking Statements
Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or
Slide 3: Zomedica Investment Highlights
Zomedica Investment Highlights • Animal health market is growing at 9% CAGR, and is expected to reach $88.6 billion by 2028(1) • Diagnostics are expected to reach $7.8 billion by 2027(2) • Diagnostics shifting towards point of care (POC) offerings providing faster diagnosis for owners, and often bet
Slide 4: Experienced Management Team with Decades of Expertise
EXPERIENCED MANAGEMENT TEAM WITH DECADESOF EXPERTISE Larry Heaton Ann Cotter Greg Blair Adrian Lock Mike Schilk Tony Blair Chief Executive Chief Financial VP, Bus Dev & CEO, PulseVet VP, Sales VP, Operations Officer Officer Strategic Planning 35+ Years of Experience 30+ Years of Experience 30+
Slide 5: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas • Expand installed base of clinical sites TRUFORMA® • Drive assay utilization • Expand assay offerings • Launch into small animal market ProPulse® w/ X-TRODE • Expand Equine Indications for Use to grow utilization • Expand international adoption Technology • Leverage st
Slide 6: Revolutionary lab quality immunoassay diagnostics at the point of care in minutes
Revolutionary lab quality immunoassay diagnostics at the point of care in minutes.
Slide 7: TRUFORMA Seeks to Change this Dynamic for Veterinarians, Patients and Pet Owners
Zomedica believes that existing in-clinic testing platforms do not provide the accuracy and precision necessary for the timely diagnosis and treatment of certain conditions. TRUFORMA Seeks to Change this Dynamic for Veterinarians, Patients and Pet Owners 7
Slide 8: Proven Bulk Acoustic Wave Technology and Broad IP Portfolio
Based on Proven and Highly Sensitive Bulk Acoustic Wave (BAW) Technology Developed and Commercialized by Qorvo in the Telecom, Aerospace and Human Diagnostic industries with FDA emergency use authorization for COVID testing Disposable Compact Timely and Cartridge Instrument Accurate Preloaded with D
Slide 9: Assay Development Targets
Assay Development Targets Multiple assay targets will drive utility for the practitioner. On the Market In Development Potential Opportunities Adrenal & Thyroid Panel for Expanding into high value Becoming a broad based Dogs and Cats Point of Care solutions Point of Care lab solution Now Available A
Slide 10: Commercial Strategy - TRUFORMA
e°*. Commercial Strategy - TRUFORMA:
Slide 11: Three Commercial Imperatives
Three Commercial Imperatives Grow Drive Launch Installed Utilization New Base Assays Customer Leveraging Partner developing Appreciation MyZomedica portal assays Program providing easy-to- New assays read test results seamlessly Facilitates growth in and easy-to-use installed base by introduced into
Slide 12: Large Addressable Market Opportunity
Large Addressable Market Opportunity 23,000 U.S. clinics currently running in-house chemistry tests are immediate potential 50,000 placement opportunities 108,000 35,000 US Clinics Already Running International Clinics Greenfield Clinics Not Total Worldwide In-Clinic Chemistry Already Running In-Cli
Slide 13: Expanding Sales & Marketing Organization
Expanding Sales & Marketing Organization • Multiple Sales Channels Building sales team with multiple paths to sell remotely, in-person and with the assistance of Veterinarians employed by Zomedica & PulseVet • Inside Sales team • Field Sales force • Professional Services Veterinarians • PulseVet Sal
Slide 14: ProPulse Shock Wave Therapy for Equine and Small Animal use
ProPulse Shock Wave Therapy for Equine and Small Animal use
Slide 15: PulseVet Overview
PulseVet Overview • Zomedica acquired PulseVet October 1, 2021 • PulseVet manufactures veterinary shock wave therapy equipment, with wide adoption in equine uses and newly applicable to small animal market. • Approximately 1,500 systems actively in use; 75% in North America and 25% in the ROW • Razo
Slide 16: Shock Wave Therapy Opportunity
Shock Wave Therapy Opportunity: • An electrohydraulic shock wave is a high-pressure wave, useful in accelerating tissue healing. • Stimulation of angiogenic (neovascularization) and osteogenic (bone regeneration) proteins results in over 40 clinical applications in horses and 20 in small animals. •
Slide 17: Equine Growth Drivers
Equine Growth Drivers • First-time purchases by equine Veterinarians continue to grow. New • Additional units for busy practices, second locations, multiple Veterinarians. Placements • Upgrades of discontinued models and devices greater than 5 years old System • ProPulse is lighter, and smaller with
Slide 18: Small Animal Opportunity
Small Animal Opportunity Passionate Leverage Total Early Sales Addressable Adopters Footprint Market • Multiple clinical studies for • Existing commercial team • US companion animal market canine use generated by Early remains in place experiencing record growth. Adopters • Cross training of Zomedic
Slide 19: Sniffing Out Future Technologies
Sniffing Out Future Technologies
Slide 20: Business Development Opportunities
Business Development Opportunities Strong Balance Sheet • ~$271 million net cash position as of 9/30/2021 • PulseVet acquired for $71.9 million in October 2021 Add to Product Portfolio Success • PulseVet is first step in expected build-out • Actively pursuing product portfolio expansion Accelerating
Slide 21: Why invest in Zomedica?
Why invest in Zomedica? • Diagnostics Market $7.8B globally by 2027. • Humanization of Pets driving nearly 10% annual market growth. • TRUFORMA provides revolutionary accuracy at point of care, with a new assay menu increasing both customer utility and ultimately contributing to an attractive addres
Slide 22: Zomedica Outlook
Zomedica Outlook “Making Tomorrow’s Gold Standard Available Today” Investor Relations Contact: Kirin Smith, President PCG Advisory Inc 646-823-8656 | ksmith@pcgadvisory.com January 2022 NYSE American: ZOM
Slide 23: Appendix
Appendix TRUFORMA
Slide 24: Appendix - Endnotes
Appendix - Endnotes 1) Grandview Research August 2021 2) Global Market Insights 2016 pet owner survey conducted by The Human Animal Bond Research Institute Foundation in partnership with Cohen Research Group (n=1,995 pet owners). Percentages represent those responding “Strongly Agree” of “Agree” Mar
Zomedica — H.C. Wainwright BioConnect Conference 2022 on 6ix